Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study

Abstract

A simple and rapid liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay method has been developed and fully validated for simultaneous quantification of pioglitazone and candesartan in human plasma. Irbesartan was used as an internal standard. The analytes were extracted from human plasma samples by solid-phase extraction technique using a Strata-X 33 μm polymeric sorbent. The reconstituted samples were chromatographed on a C18 column by using a 80:20 (v/v) mixture of acetonitrile and 0.1% formic acid as the mobile phase at a flow rate of 0.8 mL/min. The calibration curves obtained were linear (r≥0.99) over the concentration range of 15–3000 ng/mL for pioglitazone and 5–608 ng/mL for candesartan. The results of the intra- and inter-day precision and accuracy studies were well within the acceptable limits. A run time of 2.7 min for each sample made it possible to analyze more than 300 plasma samples per day. The proposed method was found to be applicable to clinical studies.

Pioglitazone: A review of analytical methods

“…Another LC/MS/MS study was reported by Kumari Karra et al [71] for simultaneous determination of PIO and candesartan in human plasma in which Irbesartan was used as an internal standard. Solid phase extraction was used for extracting the analytes from plasma.…”

Development and validation of a sensitive LC-MS/MS method for pioglitazone: application towards pharmacokinetic and tissue distribution study in rats

“…The precursor → product ion transitions (MRM) of PGZ and IS was m / z 357.95 → 135.15 and m / z 358.00 → 94.05, respectively, which were in agreement with the previous reports. 26–30 …”

A simple, rapid and fully validated HPLC method for simultaneous quantitative bio‐analysis of rosuvastatin and candesartan in rat plasma: Application to pharmacokinetic interaction study

“…A literature review revealed several bio‐analytical methods reported for ROS (Braga, Mancila, Cassella, & Pacheco, ; Caglar & Toker, ; Darwish & Al‐malaq, ; J. Gao, Zhong, Duan, & Chen, ; C K Hull, Penman, Smith, & Martin, ; Caroline K. Hull, Martin, Warwick, & Thomas, ; Hussain, Patel, & Tan, ; Kallem, Karthik, Chakradhar, & Mullangi, ; T. R. Kumar et al, ; Lan et al, ; H. K. Lee, Ho, Hu, Tomlinson, & Wong, ; MacWan, Ionita, & Akhlaghi, ; Oudhoff, Sangster, Thomas, & Wilson, ; Xu, Ruan, Yuan, & Jiang, ) and CAN (Gao et al, ; Jeon et al, ; Kondo, Yoshida, Yoshimura, Motohashi, & Tanayama, ; J. W. Lee et al, ; Lou, Ruan, & Jiang, ; Miyabayashi, Okuda, Motohashi, Izawa, & Yashiki, ; Prajapati, Patel, Chauhan, Patel, & Patel, ; Stenhoff, Lagerström, & Andersen, ) individually or in combination with other drugs like pioglitazone, hydrochlorothiazide, ciprofloxacin, metformin, etc., using either HPLC or LC–MS/MS (Arayne, Sultana, & Tabassum, ; Pp. Kumar, Murthy, & Basaveswara Rao, ; Narapusetti, Bethanabhatla, Sockalingam, Repaka, & Saritha, ; Nasir et al, ; Shah et al, ; Trivedi, Kallem, Mullangi, & Srinivas, ; Varghese & Ravi, ; Vittal et al, ; Bharathi, Hotha, Chatki, Satyanarayana, & Venkateswarlu, ; Gonzalez, Lopez, Alonso, & Jimenez, ; Kumari Karra, Rao Pilli, Kumar Inamadugu, & Seshagiri Rao, ; Nie et al, ; Singh, Lokhandae, Dwivedi, Sharma, & Dubey, ).…”